Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.57 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.57 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20987793 | 0.93 | TDP1 (0.57) | TDP1FOLH1F2PRSS1PRSS2 | |
| SCHEMBL18737415 | 0.91 | TDP1 (0.60) | TDP1FOLH1F2PRSS1PRSS2 | |
| SCHEMBL21443600 | 0.91 | TDP1 (0.60) | TDP1FOLH1F2PRSS1PRSS2 | |
| SCHEMBL12435801 | 0.91 | TDP1 (0.60) | TDP1FOLH1F2PRSS1PRSS2 | |
| SCHEMBL19069181 | 0.91 | TDP1 (0.60) | TDP1FOLH1F2PRSS1PRSS2 | |
| SCHEMBL19735728 | 0.90 | TDP1 (0.57) | TDP1FOLH1F2PRSS1PRSS2 | |
| SCHEMBL22420154 | 0.89 | F2 (0.59) | TDP1FOLH1F2PRSS1PRSS2 | |
| SCHEMBL18469836 | 0.89 | F2 (0.59) | TDP1FOLH1F2PRSS1PRSS2 | |
| SCHEMBL19735573 | 0.89 | F2 (0.59) | TDP1FOLH1F2PRSS1PRSS2 | |
| SCHEMBL19176655 | 0.89 | F2 (0.59) | TDP1FOLH1F2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | TDP1 2059/4885FOLH1 2177/4885F2 4199/4885 |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | TDP1 710/4885FOLH1 2307/4885F2 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.